Corporate | 17 December 2009 07:03
STRATEC Biomedical Systems AG / Forecast
17.12.2009
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC provides outlook for 2010 and beyond / 2009 financial guidance
reaffirmed
- Financial forecast for 2009 reaffirmed
- 2010 revenues expected to be between Euro 96 million and Euro 102
million
- 2010 EBIT margin expected to grow by more than 0.5% points over 2009
- 2010 to 2012 revenue CAGR expected to exceed 15%
- Free cash flow to fund planned expansion and further growth
Birkenfeld, December 17, 2009
STRATEC Biomedical Systems, Birkenfeld, Germany (Frankfurt: SBS; Prime
Standard), has today published medium-term financial guidance based on
recent clients' forecasts and statements, allied to the Company's current
development pipeline. Current trading continues in line with management's
expectations, and STRATEC today reaffirms its previous guidance for 2009.
As first detailed on April 8, 2009, guidance for 2009 calls for revenue
growth of between 20% and 30% (Euro 73.2 million to Euro 79.3 million), and
for an EBIT margin of between 18.5% and 19.5%.
For the financial year 2010, STRATEC expects sales in the range of Euro 96
million to Euro 102 million. The four major development programs ongoing
and an increasing share of consumables and replacement parts will drive the
EBIT margin. Management expects the EBIT margin to expand by more than 0.5%
points over that achieved in 2009.
Based on the stable growth of all programs, as well as the prospects and
forecasts for the new programs, STRATEC expects to continue its growth for
the coming years. Specifically, the compound annual growth rate (CAGR) for
sales over the years 2010 to 2012 is expected to exceed 15%.
'Our continuous growth trajectory is based on solid performance across all
our major projects and on the development of new systems.' stated Hermann
Leistner, CEO of STRATEC, adding: 'Our leading position as an independent
OEM supplier is strengthened by the continuous outsourcing trend in our
industry as well as the strong demand for molecular diagnostics
technologies and chemiluminescence assay analyzers. STRATEC's state of the
art technologies, such as random access analyzers, meet the requirements of
our customers to offer solutions fitting the modern laboratory and blood
bank workflows.'
In January 2010 STRATEC will present at the J.P. Morgan Global Healthcare
Conference in San Francisco, USA (January 11 - 14, 2010) and at the
Cheuvreux German Corporate Conference in Frankfurt, Germany (January 18 -
20, 2010). For further conference participations please check STRATEC's
financial calendar at www.stratec-biomedical.de > Investor Relations > IR
News > Financial Calendar.
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
Email: ir@stratec-biomedical.de
17.12.2009 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in München, Düsseldorf, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------